{"name":"Ascletis Pharma","slug":"ascletis","ticker":"1672.HK","exchange":"HKEX","domain":"ascletis.com","description":"Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People's Republic of China.","hq":"Hangzhou, China","founded":2015,"employees":"202","ceo":"Jinzi J. Wu","sector":"Virology / Infectious Disease","stockPrice":17.28,"stockChange":0.13,"stockChangePercent":0.76,"marketCap":"$2.7B","metrics":{"revenue":298890.22956,"revenueGrowth":-26.2,"grossMargin":26,"rdSpend":0,"netIncome":-53039751.3876,"cash":280604721.9169242,"dividendYield":0,"peRatio":-61.7,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"danoprevir patent cliff ($123.8M at risk)","drug":"danoprevir","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"oncology","drugs":[{"name":"ASC09F","genericName":"ASC09F","slug":"asc09f","indication":"Other","status":"phase_1"},{"name":"ASC11 tablets","genericName":"ASC11 tablets","slug":"asc11-tablets","indication":"Other","status":"phase_1"},{"name":"ASC18","genericName":"ASC18","slug":"asc18","indication":"Other","status":"phase_1"},{"name":"ASC30 tablets","genericName":"ASC30 tablets","slug":"asc30-tablets","indication":"Other","status":"phase_2"},{"name":"ASC30","genericName":"ASC30","slug":"asc30","indication":"Other","status":"phase_1"},{"name":"ASC47","genericName":"ASC47","slug":"asc47","indication":"Other","status":"phase_1"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"ASC41","genericName":"ASC41","slug":"asc41","indication":"Non-alcoholic steatohepatitis (NASH)","status":"phase_1"},{"name":"ASC40","genericName":"ASC40","slug":"asc40","indication":"Chronic hepatitis B infection","status":"phase_3"},{"name":"ASC40 tablets","genericName":"ASC40 tablets","slug":"asc40-tablets","indication":"Chronic hepatitis B infection","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"ASC22","genericName":"ASC22","slug":"asc22","indication":"Non-small cell lung cancer (NSCLC)","status":"phase_2"}]}],"pipeline":[{"name":"ASC09F","genericName":"ASC09F","slug":"asc09f","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASC11 tablets","genericName":"ASC11 tablets","slug":"asc11-tablets","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASC18","genericName":"ASC18","slug":"asc18","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASC30 tablets","genericName":"ASC30 tablets","slug":"asc30-tablets","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASC41","genericName":"ASC41","slug":"asc41","phase":"phase_1","mechanism":"ASC41 is a thyroid hormone receptor beta (THRβ) agonist that modulates lipid metabolism.","indications":["Non-alcoholic steatohepatitis (NASH)","Hypercholesterolemia"],"catalyst":""},{"name":"ASC22","genericName":"ASC22","slug":"asc22","phase":"phase_2","mechanism":"ASC22 is a humanized monoclonal antibody that blocks the PD-L1 checkpoint, enhancing anti-tumor immune responses by preventing PD-L1 from binding to PD-1 and B7.1 on immune cells.","indications":["Non-small cell lung cancer (NSCLC)","Hepatocellular carcinoma (HCC)"],"catalyst":""},{"name":"ASC30","genericName":"ASC30","slug":"asc30","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASC40","genericName":"ASC40","slug":"asc40","phase":"phase_3","mechanism":"ASC40 is a hepatitis B virus (HBV) capsid assembly modulator that disrupts viral particle formation.","indications":["Chronic hepatitis B infection"],"catalyst":""},{"name":"ASC40 tablets","genericName":"ASC40 tablets","slug":"asc40-tablets","phase":"phase_3","mechanism":"ASC40 is a hepatitis B virus (HBV) capsid assembly modulator that disrupts viral particle formation.","indications":["Chronic hepatitis B infection"],"catalyst":""},{"name":"ASC47","genericName":"ASC47","slug":"asc47","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-03-15","type":"earnings","headline":"Ascletis Pharma Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Ascletis Pharma reported its financial results for the fourth quarter and full year 2023, highlighting a net loss of $123.8 million and $444.8 million, respectively.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Ascletis Pharma Enters into Licensing Agreement with Jiangsu Hengrui Medicine","summary":"Ascletis Pharma entered into a licensing agreement with Jiangsu Hengrui Medicine to develop and commercialize its lead product, danoprevir, in China.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxNMi1pZlNRbFh2TVg4OXdOeU8zblRPNHlERVROWnYtdkRlUTFWUzZZRHJsaUFqQ09Jb1NBT2xDOTVkMkw2MXRxcERXYXpKbWVWYzRabUs5eFNqOHJJX3U0U1VheWd6dlpRV08zR0RGRzFlaU81NGR0eEVoSU15dlNnMElYaFJidFppZFdiWGdnZjBFc1ZON3duUkR1WmdEb0U5dGNOSnJRbmJ0MEIxaGR5cnY0SlhtU0hBUU1VVXVXemVyNjRVSkIyV1dESWVacjhRbWc?oc=5","date":"2026-04-04","type":"pipeline","source":"The Globe and Mail","summary":"Ascletis Pharma, Inc. (1672) Gets a Hold from Goldman Sachs - The Globe and Mail","headline":"Ascletis Pharma, Inc. (1672) Gets a Hold from Goldman Sachs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOcE1CblYzd3BPd0d4dWFUOFN2NU5idjBMNVlhOEd4Zk9QOXJMNE1mM0ZuUTRxbnlIdm9WaGdnS09hbU0yR3h4VnEta1F6TXg3MGZwNjVMNC1zb1hsMHRwemJBQVVIRVpfaU5OVDZTZ2xoYW5QWXFjaFI1cU5EMFM5alRaQnpwbFRPZTN4V3JzTXA2OExQcTVLT3dn?oc=5","date":"2026-04-01","type":"pipeline","source":"Moomoo","summary":"Ascletis Pharma's Loss Widens 20% in 2025; Shares Rise 5% - Moomoo","headline":"Ascletis Pharma's Loss Widens 20% in 2025; Shares Rise 5%","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-04","type":"trial","source":"simplywall.st","summary":"Ascletis Pharma (SEHK:1672) Is Up 5.4% After HK$844m Follow-On Offering And Positive Phase III Acne Data - Has The Bull Case Changed? - simplywall.st","headline":"Ascletis Pharma (SEHK:1672) Is Up 5.4% After HK$844m Follow-On Offering And Positive Phase III Acne Data - Has The Bull ","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPUHdqbzNHWHcwQkxDcmFyczZ6OVQxS0FOdVlrdzBXTDhwelJDZDZnbVFyYnBReXRic2ZVbHFZSGFxNldSTHFjNTRuQjI4dnJxbU1xR0pvTTN0TS1MTG5tbXpXZFBWZDFPMDEwN2puTGVEOUxSa2FWbU9FcWthckttWW8zUUJoamlfRDlB?oc=5","date":"2026-02-03","type":"trial","source":"thebambooworks.com","summary":"BRIEF: Ascletis raises $107 million to fund obesity drug trials - thebambooworks.com","headline":"BRIEF: Ascletis raises $107 million to fund obesity drug trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNLUZCVU96MjRjN0ZOVE1CblhmeEZaLTdsb2NURGtfUWcyRF9KYWd5NUhZbUpQWHdaZ3BPZ0Jrc2pFaHVReFl5NTFjT1FTendiNkROUVIxelBMdTM1WldFcXpnSHBoTnNzeE1XUlR0OVJJRnBNN3BjX3IwSEJjTkhFQzA2OERGMTYwV1JJ?oc=5","date":"2025-12-15","type":"pipeline","source":"Yahoo Finance","summary":"Ascletis Pharma (SEHK:1672): Reassessing Valuation After a Sharp One-Day Pullback and Powerful 12-Month Rally - Yahoo Finance","headline":"Ascletis Pharma (SEHK:1672): Reassessing Valuation After a Sharp One-Day Pullback and Powerful 12-Month Rally","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOSVRxQXlnRFlIWGFWNm56bFV0cGtxcGh3cGU4Y25aWDA4WUM1N250VF82a2FabmN1UU1nVlpqb2ZLaEp6cVRwaUs5cHM3WnZaVTkwdmRKd2J6Vm5yRDFjQUZjN19tX1JzRG9MaUg0ZzBUYzFRV2tBQXV2dWVobzFEcw?oc=5","date":"2025-11-14","type":"trial","source":"Yahoo Finance","summary":"Why Ascletis Pharma (SEHK:1672) Is Up 45.4% After Unveiling New Obesity Drug Data and US IND Plans - Yahoo Finance","headline":"Why Ascletis Pharma (SEHK:1672) Is Up 45.4% After Unveiling New Obesity Drug Data and US IND Plans","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPaG50UWdteEdnT3hxXzNWWUdJYXVKNGpSNGV6bzdLd1FtSW9VM19qOGhYWTA3UGk5cW1hNERFTDNsLTF3ODNjeVh1NC1KYjkzS1ZNcmt5czdQOFJoVXlINDhka0lpTlN5YXI4ZTJ4TjdvQVJSSXJpQlpSSDEzUzdJSWRfZ2VoeDZiN2N0RTdBdjJWMU5Yd3gtcnJEZjZ5Y29RWktF?oc=5","date":"2024-09-27","type":"earnings","source":"thebambooworks.com","summary":"Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs - thebambooworks.com","headline":"Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOOENyR200a1RDUWlCazhTU2FtNDBWZ01MS2NCRlpMUEUzOU1EQk5ZUGZVQ2NTa21ZX0VFVlY2alA0ZXRDOTd6QnVxMlJaVWo2ZHBrWEZvVEtUMjdYWk43TDdrNmgzYzZWVHFFdFJTQkxlb2phdm1oQ3BUR09SZ0JwTnZDWHhwOEZrN1FycmFIZWNRRlVtNnU3R0RqNWI?oc=5","date":"2022-04-04","type":"pipeline","source":"The Standard (HK)","summary":"Ascletis seeks to market Covid tablet in HK - The Standard (HK)","headline":"Ascletis seeks to market Covid tablet in HK - The Standard (HK)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTFA3ZzVqVlEzQVhydm14OEdCVVlIQjY2V0dOQTdwY2hJZVhZNmRsbjhDa2ZxTGZZYVVqdlB4dWlGM3lNemt0T0ZwSGZ5WUVNeWotQW5lZ1RobzZHY2hhQzZoMDRQampydnE3?oc=5","date":"2018-08-08","type":"pipeline","source":"TradingView","summary":"Technical Analysis of Ascletis Pharma, Inc. (HKEX:1672) - TradingView","headline":"Technical Analysis of Ascletis Pharma, Inc. (HKEX:1672)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOekg1RDRJSTBfZXNEZVI1WU9VVm81YmR6VGMyT196Q0IyX1hPQ3ZqWDdGcWtWenZZbGRfQm5kSmU1UWQyZGJHNUNNWVhvaklhZk4zVTZrRUlZQnRiZkNoRl81dW1UNEVhUmhlU0RrLTVhaTRTZ1EzTGNUZVVBUnBTbTU3SEtlNGo5VXNYMXJlMy1Lb0dINEFENTNoNlpIN21BcXo5SVJGRVAxblZjeHFOWmZtWEtkRXUtRkprUnRLYw?oc=5","date":"2018-07-26","type":"pipeline","source":"Reuters","summary":"Chinese biotech firm Ascletis raises $400 million in HK IPO: sources - Reuters","headline":"Chinese biotech firm Ascletis raises $400 million in HK IPO: sources","sentiment":"neutral"}],"patents":[{"drugName":"danoprevir","drugSlug":"danoprevir","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":123800000}],"drugCount":10,"phaseCounts":{"phase_1":6,"phase_2":2,"phase_3":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Gilead Sciences","Merck & Co.","Bristol Myers Squibb"],"therapeuticFocus":["Virology","Infectious Disease"],"financials":{"source":"yahoo_finance","revenue":298890.22956,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":298890.22956},{"period":"2024-12-31","value":189090.81091},{"period":"2023-12-31","value":8341218.65492},{"period":"2022-12-31","value":7971879.9393}],"grossProfit":77670.19279,"grossProfitHistory":[{"period":"2025-12-31","value":77670.19279},{"period":"2024-12-31","value":108325.60095},{"period":"2023-12-31","value":3830452.2023},{"period":"2022-12-31","value":-3639150.6648399998}],"rdSpend":60286955.16381,"rdSpendHistory":[{"period":"2025-12-31","value":60286955.16381},{"period":"2024-12-31","value":44567362.95738},{"period":"2023-12-31","value":31949567.48237},{"period":"2022-12-31","value":39365965.53054}],"sgaSpend":4461540.94144,"operatingIncome":-65805370.77792,"operatingIncomeHistory":[{"period":"2025-12-31","value":-65805370.77792},{"period":"2024-12-31","value":-56337418.491349995},{"period":"2023-12-31","value":-44245186.40816},{"period":"2022-12-31","value":-50055123.163329996}],"netIncome":-53039751.3876,"netIncomeHistory":[{"period":"2025-12-31","value":-53039751.3876},{"period":"2024-12-31","value":-44352480.33672},{"period":"2023-12-31","value":-21328352.84555},{"period":"2022-12-31","value":-46402118.61211}],"eps":-0.3701,"epsHistory":[{"period":"2025-12-31","value":-0.3701},{"period":"2024-12-31","value":-0.3005},{"period":"2023-12-31","value":-0.1347},{"period":"2022-12-31","value":-0.2896}],"cash":212747500.95801,"cashHistory":[{"period":"2025-12-31","value":212747500.95801},{"period":"2024-12-31","value":127592819.7421},{"period":"2023-12-31","value":48653227.76709},{"period":"2022-12-31","value":59508042.50936}],"totalAssets":304568112.24925,"totalLiabilities":19492860.281969998,"totalDebt":760195.16966,"equity":285075251.96728,"operatingCashflow":-61425184.57352,"operatingCashflowHistory":[{"period":"2025-12-31","value":-61425184.57352},{"period":"2024-12-31","value":-50342517.614829995},{"period":"2023-12-31","value":-32983303.21715},{"period":"2022-12-31","value":-29839502.68128}],"capex":-290636.85044,"capexHistory":[{"period":"2025-12-31","value":-290636.85044},{"period":"2024-12-31","value":-316576.04196},{"period":"2023-12-31","value":-2823539.94966},{"period":"2022-12-31","value":-2122444.8697699998}],"freeCashflow":-61715821.42396,"dividendsPaid":null,"buybacks":-12023110.03306,"employees":202,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":17.28,"previousClose":17.15,"fiftyTwoWeekHigh":19.86,"fiftyTwoWeekLow":5.3,"fiftyTwoWeekRange":"5.3 - 19.86","fiftyDayAverage":16.44,"twoHundredDayAverage":13.79,"beta":0.47,"enterpriseValue":2246218381.72972,"forwardPE":-61.7,"priceToBook":7.69,"priceToSales":8992.28,"enterpriseToRevenue":7515.19,"enterpriseToEbitda":-32.31,"pegRatio":0,"ebitda":-69512170.85424416,"ebitdaMargin":0,"freeCashflow":-43964128.19371584,"operatingCashflow":-61425184.57352,"totalDebt":760195.16966,"debtToEquity":0.3,"currentRatio":15.05,"returnOnAssets":-14.5,"returnOnEquity":-18.5,"analystRating":"","recommendationKey":"none","numberOfAnalysts":3,"targetMeanPrice":22.45,"targetHighPrice":32.38,"targetLowPrice":15.95,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":65.2,"institutionHeldPercent":11.9,"sharesOutstanding":1055344320,"floatShares":228627031,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":-0.43,"epsForward":-0.28,"revenuePerShare":0,"bookValue":2.25,"officers":[{"age":61,"name":"Dr. Jinzi  Wu Ph.D.","title":"Founder, Chairman & CEO"},{"age":51,"name":"Ms. Hejingdao  Wu","title":"Senior VP of Operations & Executive Director"},{"age":57,"name":"Dr. Kristjan Sigurdur Gudmundsson","title":"Senior Consultant & Head of Discovery"},{"age":74,"name":"Dr. George Zhengzhi Hill","title":"Senior Consultant & Chief Medical Advisor"},{"age":65,"name":"Mr. John P. Gargiulo M.B.A.","title":"Chief Business Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.ascletis.com","phone":"86 571 8538 9730"}}